120 related articles for article (PubMed ID: 12609702)
1. Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses.
Shinderman M; Maxwell S; Brawand-Amey M; Golay KP; Baumann P; Eap CB
Drug Alcohol Depend; 2003 Mar; 69(2):205-11. PubMed ID: 12609702
[TBL] [Abstract][Full Text] [Related]
2. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokar M; Hämmig R; Gothuey I; Monnat M; Eap CB
Clin Pharmacol Ther; 2006 Dec; 80(6):668-81. PubMed ID: 17178267
[TBL] [Abstract][Full Text] [Related]
3. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment.
Eap CB; Bourquin M; Martin J; Spagnoli J; Livoti S; Powell K; Baumann P; Déglon J
Drug Alcohol Depend; 2000 Dec; 61(1):47-54. PubMed ID: 11064183
[TBL] [Abstract][Full Text] [Related]
4. Correlation between high methadone doses and methadone serum levels in methadone maintenance treatment (MMT) patients.
Adelson M; Peles E; Bodner G; Kreek MJ
J Addict Dis; 2007; 26(1):15-26. PubMed ID: 17439864
[TBL] [Abstract][Full Text] [Related]
5. Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.
Shiran MR; Lennard MS; Iqbal MZ; Lagundoye O; Seivewright N; Tucker GT; Rostami-Hodjegan A
Br J Clin Pharmacol; 2009 Jan; 67(1):29-37. PubMed ID: 19133059
[TBL] [Abstract][Full Text] [Related]
6. Methadone maintenance treatment: is it possible to adapt the daily doses to the metabolic activity of the patient?
Charlier C; Dessalles MC; Plomteux G
Ther Drug Monit; 2001 Feb; 23(1):1-3. PubMed ID: 11206036
[TBL] [Abstract][Full Text] [Related]
7. Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients.
Uehlinger C; Crettol S; Chassot P; Brocard M; Koeb L; Brawand-Amey M; Eap CB
J Clin Psychopharmacol; 2007 Jun; 27(3):273-8. PubMed ID: 17502774
[TBL] [Abstract][Full Text] [Related]
8. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.
Eap CB; Buclin T; Baumann P
Clin Pharmacokinet; 2002; 41(14):1153-93. PubMed ID: 12405865
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 2D6 genotype and methadone steady-state concentrations.
Eap CB; Broly F; Mino A; Hämmig R; Déglon JJ; Uehlinger C; Meili D; Chevalley AF; Bertschy G; Zullino D; Kosel M; Preisig M; Baumann P
J Clin Psychopharmacol; 2001 Apr; 21(2):229-34. PubMed ID: 11270921
[TBL] [Abstract][Full Text] [Related]
10. Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity.
Mouly S; Bloch V; Peoc'h K; Houze P; Labat L; Ksouda K; Simoneau G; Declèves X; Bergmann JF; Scherrmann JM; Laplanche JL; Lepine JP; Vorspan F
Br J Clin Pharmacol; 2015 Jun; 79(6):967-77. PubMed ID: 25556837
[TBL] [Abstract][Full Text] [Related]
11. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokkar M; Gothuey I; Hämmig R; Monnat M; Hüttemann H; Baumann P; Eap CB
Clin Pharmacol Ther; 2005 Dec; 78(6):593-604. PubMed ID: 16338275
[TBL] [Abstract][Full Text] [Related]
12. Enantiomeric metabolic interactions and stereoselective human methadone metabolism.
Totah RA; Allen KE; Sheffels P; Whittington D; Kharasch ED
J Pharmacol Exp Ther; 2007 Apr; 321(1):389-99. PubMed ID: 17259447
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate.
Boulton DW; Arnaud P; DeVane CL
Clin Pharmacol Ther; 2001 Jul; 70(1):48-57. PubMed ID: 11452244
[TBL] [Abstract][Full Text] [Related]
14. Using saccadic eye movements as objective measures of tolerance in methadone dependent individuals during the hydromorphone challenge test.
Melichar JK; Myles JS; Eap CB; Nutt DJ
Addict Biol; 2003 Mar; 8(1):59-66. PubMed ID: 12745417
[TBL] [Abstract][Full Text] [Related]
15. Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity.
Eap CB; Buclin T; Cucchia G; Zullino D; Hustert E; Bleiber G; Golay KP; Aubert AC; Baumann P; Telenti A; Kerb R
Eur J Clin Pharmacol; 2004 Jun; 60(4):237-46. PubMed ID: 15114429
[TBL] [Abstract][Full Text] [Related]
16. Three oral formulations of methadone. A clinical and pharmacodynamic comparison.
Gourevitch MN; Hartel D; Tenore P; Freeman K; Marion I; Hecht J; Lowinson J
J Subst Abuse Treat; 1999 Oct; 17(3):237-41. PubMed ID: 10531630
[TBL] [Abstract][Full Text] [Related]
17. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients.
Foster DJ; Somogyi AA; Dyer KR; White JM; Bochner F
Br J Clin Pharmacol; 2000 Nov; 50(5):427-40. PubMed ID: 11069437
[TBL] [Abstract][Full Text] [Related]
18. Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo.
Lowry JA; Kearns GL; Abdel-Rahman SM; Nafziger AN; Khan IS; Kashuba AD; Schuetz EG; Bertino JS; van den Anker JN; Leeder JS
Clin Pharmacol Ther; 2003 Mar; 73(3):209-22. PubMed ID: 12621386
[TBL] [Abstract][Full Text] [Related]
19. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro.
Wang JS; DeVane CL
Drug Metab Dispos; 2003 Jun; 31(6):742-7. PubMed ID: 12756206
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic evidence to support clinical decision making for peripartum methadone treatment.
Bogen DL; Perel JM; Helsel JC; Hanusa BH; Romkes M; Nukui T; Friedman CR; Wisner KL
Psychopharmacology (Berl); 2013 Jan; 225(2):441-51. PubMed ID: 22926004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
